Literature DB >> 19132209

Drug-eluting balloon: very short-term exposure and overlapping.

Bodo Cremers1, Ulrich Speck, Nicola Kaufels, Dirk Mahnkopf, Michael Kühler, Michael Böhm, Bruno Scheller.   

Abstract

Paclitaxel balloon coating has shown promising effects in inhibiting restenosis in initial clinical trials. The aim of the present study was to evaluate the influence of two critical features of drug-eluting balloon (DEB) application - inflation time and increased dose due to overlapping balloons. Fifty-six stainless steel stents were implanted in the left anterior descending and circumflex coronary arteries of 28 domestic pigs using a 1.2:1.0 overstretch ratio. Stents were mounted on conventional uncoated and paclitaxel-coated angioplasty balloon catheters. The animals were randomized to five different treatments with a range of short (10 seconds [s] inflation using 1 DEB) to extended (2x60 s inflation using 2 DEB) intima contact time. After 28 days, quantitative angiography and histomorphometry of the stented arteries was performed on a total of 23 pigs. Paclitaxel balloon coating led to a marked reduction of parameters characterizing in-stent stenosis: Late lumen loss was 1.37 +/- 0.49 mm for uncoated balloons, 0.23 +/- 0.42 mm for one coated balloon 60 s inflation time, 0.37 +/- 0.28 mm for 10 s inflation time and 0.30 +/- 0.19 mm for the vessel segment treated by two coated balloons with 60 s inflation each. Neointimal areas were 4.26 +/- 1.18, 1.68 +/- 0.23, 1.83 +/- 0.40 and 1.67 +/- 0.46 mm(2), respectively (p = 0.001 versus control, p > 0.05 between paclitaxel-treated groups). Despite the marked reduction of neointimal proliferation, endothelialization of stent struts was present in all samples. DEB were found to effectively reduce neointimal proliferation regardless of inflation time and dose within the tested range. No adverse reactions were seen as dose was increased to more than three times the clinically tested dose.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19132209

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

1.  The paclitaxel-eluting PTCA-balloon in combination with a cobalt-chromium stent in two different sequences to treat de novo coronary artery lesions: an angiographic follow up study.

Authors:  Upendra Kaul; Martin Unverdorben; Ralf Degenhardt; Ashok Seth; Vinay K Bahl; Shirish M S Hiremath; Praveen Chandra; Ajit S Mullesari; P S Sandhu; Seshagiri Rao; Oommen George; Hanns Ackermann; Michael Boxberger
Journal:  Indian Heart J       Date:  2013-09-13

2.  Treatment of small coronary arteries with a paclitaxel-coated balloon catheter.

Authors:  Martin Unverdorben; Franz X Kleber; Hubertus Heuer; Hans-Reiner Figulla; Christian Vallbracht; Matthias Leschke; Bodo Cremers; Stefan Hardt; Michael Buerke; Hanns Ackermann; Michael Boxberger; Ralf Degenhardt; Bruno Scheller
Journal:  Clin Res Cardiol       Date:  2010-01-06       Impact factor: 5.460

3.  Opportunities and limitations of drug-coated balloons in interventional therapies.

Authors:  B Scheller
Journal:  Herz       Date:  2011-05       Impact factor: 1.443

Review 4.  Drug-coated balloons for coronary and peripheral interventional procedures.

Authors:  Jochen Wöhrle
Journal:  Curr Cardiol Rep       Date:  2012-10       Impact factor: 2.931

5.  Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter.

Authors:  Bodo Cremers; John L Toner; Lewis B Schwartz; Randolf von Oepen; Ulrich Speck; Nicola Kaufels; Yvonne P Clever; Dirk Mahnkopf; Michael Böhm; Bruno Scheller
Journal:  Clin Res Cardiol       Date:  2012-06       Impact factor: 5.460

6.  Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis.

Authors:  Yvonne P Clever; Bodo Cremers; Wolfgang von Scheidt; Michael Böhm; Ulrich Speck; Bruno Scheller
Journal:  Clin Res Cardiol       Date:  2013-09-26       Impact factor: 5.460

7.  [Efficacy of drug-coated balloon and common balloon for treatment of superficial femoral artery and popliteal artery arteriosclerosis obliterans: prospective randomized controlled triac].

Authors:  Jing-Yuan Lu; Jian-Ping Gu; Wen-Jian Xu; Wen-Sheng Lou; Tao Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-03-20

Review 8.  [Drug-coated balloons in the treatment of peripheral artery disease (PAD). History and current level of evidence].

Authors:  M Herten; S Stahlhoff; B Imm; E Schönefeld; A Schwindt; G B Torsello
Journal:  Radiologe       Date:  2016-03       Impact factor: 0.635

9.  Analysis of potential cost-savings after introduction of drug-eluting balloon angioplasty for in-stent restenosis or small vessel disease.

Authors:  Kyungil Park; Tae-Eun Kim; Kyung-Woo Park; Hyun-Jae Kang; Bon-Kwon Koo; Hyo-Soo Kim
Journal:  Korean Circ J       Date:  2011-12-31       Impact factor: 3.243

10.  Downstream Paclitaxel Released Following Drug-Coated Balloon Inflation and Distal Limb Wound Healing in Swine.

Authors:  Juan F Granada; Marco Ferrone; Gilberto Melnick; Lesley Crookall; Daniel Schulz-Jander; Stefan Tunev; Robert J Melder; Grzegorz L Kaluza
Journal:  JACC Basic Transl Sci       Date:  2021-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.